Dormant cancer cells and polyploid giant cancer cells: The roots of cancer recurrence and metastasis

Yuqi Jiao,Yongjun Yu,Minying Zheng,Man Yan,Jiangping Wang,Yue Zhang,Shiwu Zhang
DOI: https://doi.org/10.1002/ctm2.1567
IF: 8.554
2024-02-17
Clinical and Translational Medicine
Abstract:1. PGCCs have emerged as a key regulator of tumour dormancy and reactivation. 2. Abnormal cell cycle regulation in PGCCs enables them to enter a reversibly dormant state and evade cancer therapy. 3. PGCCs achieve dormancy through endoreduplication and cell cycle arrest. 4. PGCCs can exit dormancy and recur via asymmetric division, thereby generating aggressive diploid progeny. Tumour cell dormancy is critical for metastasis and resistance to chemoradiotherapy. Polyploid giant cancer cells (PGCCs) with giant or multiple nuclei and high DNA content have the properties of cancer stem cell and single PGCCs can individually generate tumours in immunodeficient mice. PGCCs represent a dormant form of cancer cells that survive harsh tumour conditions and contribute to tumour recurrence. Hypoxic mimics, chemotherapeutics, radiation and cytotoxic traditional Chinese medicines can induce PGCCs formation through endoreduplication and/or cell fusion. After incubation, dormant PGCCs can recover from the treatment and produce daughter cells with strong proliferative, migratory and invasive abilities via asymmetric cell division. Additionally, PGCCs can resist hypoxia or chemical stress and have a distinct protein signature that involves chromatin remodelling and cell cycle regulation. Dormant PGCCs form the cellular basis for therapeutic resistance, metastatic cascade and disease recurrence. This review summarises regulatory mechanisms governing dormant cancer cells entry and exit of dormancy, which may be used by PGCCs, and potential therapeutic strategies for targeting PGCCs.
oncology,medicine, research & experimental
What problem does this paper attempt to address?